Improving the diagnosis of prostate cancer by telomerase-positive circulating tumor cells: A prospective pilot study.

ABSTRACT:

Background

Prostate-specific antigen (PSA) testing is limited in identifying prostate cancer (PCa) with modestly elevated PSA levels. Therefore, a robust method for the diagnosis of PCa is urgently needed.

Methods

A total of 203 men with a PSA level of ≥4 ng/ml were eligible for enrollment in this study from July 2018 to May 2021, and randomly divided into a training set (n=78) and a validation set (n=125). Circulating tumor cells (CTCs) were detected using telomerase-based CTC detection (TBCD), and the diagnostic ability was evaluated using receiver operating characteristic (ROC) and logistic regression analyses.

Findings

In the training set, the area under the curve (AUC) of CTCs was 0.842 with a sensitivity of 80.33% and specificity of 82.35%. In the validation set

SUBMITTER: Yang Z 

PROVIDER: S-EPMC8808177 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature